Child and Adolescent Psychiatry and Mental Health
June 4, 2025
Sarah Forsberg, Amanda E. Downey, Lindsey D Bruett et al.
5 citations
Psychedelic-assisted therapy (PAT) is gaining recognition as a promising intervention for treatment-refractory mental health conditions in adults. While interest in its applications for adolescents is growing, critical gaps remain in understanding safe and effective delivery of PAT to this vulnerable population, including implications for caregiver/family (used interchangeably) involvement in...
JAMA Psychiatry
March 1, 2025
Michelle Matvey, Dennis Parker Kelley, Ellen Bradley et al.
12 citations
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment...
Journal of Psychoactive Drugs
2025
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
16 citations
Qualitative studies and anecdotal reports suggest that experiences with ayahuasca, a psychedelic brew found in Central and South America, may be followed by individuals enduringly feeling more grateful and connected to nature. Yet, to date, these changes have been understudied. Here, participants (N = 54) completed validated surveys related to gratitude, nature relatedness, and nature...
Am J Psychiatry
2025
Aaron Wolfgang, Vetisha L. McClair, Paula P. Schnurr et al.
6 citations
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Journal of Humanistic Psychology
February 27, 2024
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
5 citations
Psychedelic drugs are currently being investigated for their potential to facilitate a variety of long-lasting psychological changes. One area that has yet to be systematically investigated in psychedelic research, however, regards changes in aesthetic experience (i.e., one’s attitudes, perceptions, and expression of art). This is surprising given the wealth of anecdotes directly noting...
Journal of Psychopharmacology
December 14, 2022
Emma Morton, Kimberly Sakai, Amir Ashtari et al.
75 citations
Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent applications for bipolar disorder (BD). Knowledge of the risks and benefits of psilocybin in BD is limited to case studies. Aim: To support the design of clinical trials, we surveyed experiences of psilocybin use in people with BD....
PLoS One
December 14, 2022
Meghan DellaCrosse, Mollie Pleet, Emma Morton et al.
28 citations
Objectives People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have...
Journal of Humanistic Psychology
June 12, 2021
Gabrielle Agin-Liebes, Eve Ekman, B. Anderson et al.
47 citations
The primary objective of this qualitative study was to explore the therapeutic trajectories of individuals undergoing psilocybin-assisted group therapy. This interpretive phenomenological analysis focused on an enriched study sample of gay-identified cisgender men ( n = 9) with human immunodeficiency virus diagnosed before 1996 and clinically significant trauma symptoms. Microphenomenological...